Tony Coles is executive chairman and CEO of Cerevel Therapeutics, a biopharmaceutical company specializing in the development of treatment options for diseases of the central nervous system, such as Alzheimer’s, epilepsy, Parkinson’s, and schizophrenia.

Dr. Coles is the former chairman and chief executive officer of Onyx Pharmaceuticals, Inc., which was acquired by Amgen in 2013 for $10.5 billion. Under his leadership, Onyx introduced two new innovative cancer medicines to patients and established the company’s international presence outside of the United States. Prior to joining Onyx in 2008, he was president, CEO, and a member of the board of directors of NPS Pharmaceuticals, Inc. Before joining NPS Pharmaceuticals in 2005, Dr. Coles was senior vice president of commercial operations at Vertex Pharmaceuticals Incorporated, which he joined in 2002.